|Day Low/High||49.37 / 49.93|
|52 Wk Low/High||37.62 / 51.84|
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Clinton goes after the drug companies again -- for starters.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
The sector seems to be rebounding after tumbling by more than 40%.
The mobile-gaming market is expected to surpass console games this year, according to Deloitte.
Our first upside target is the $50 to $52 area and a close below $40 would extend the base.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
U.K. banks continue to get crushed in the wake of last week's Brexit vote as gold, a typical safe-haven investment, surged ahead.
Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
It is hard to see much growth in the market overall, until earnings growth returns.
The M&A activity is an incredible and a welcome sign.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...
Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.
The ECB's monetary stimulus is working, and more may be on the way.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
And four other things you need to know now.
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
Stocks ended the day lower in a quieter session of trading compared to Wednesday's blowout rally.
Selection of stocks is tailor made for investor, given market parameters.
The European economy is growing and the volatility from the Greek exit drama is keeping a lid on stock valuations.
It's almost impossible to get too excited about its success.
As health-care stocks rally, it's time for politicians to move on.